We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+1.37%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$5.76B
AUM Growth
+$32.7M
Cap. Flow
+$188M
Cap. Flow %
3.27%
Top 10 Hldgs %
50.49%
Holding
248
New
70
Increased
46
Reduced
39
Closed
50

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$136M
2
FRPT icon
Freshpet
FRPT
+$91.3M
3
ROST icon
Ross Stores
ROST
+$81.3M
4
FIVE icon
Five Below
FIVE
+$72.6M
5
EXAS
Exact Sciences
EXAS
+$64.3M

Top Sells

Rank Stock Value
1
DG icon
Dollar General
DG
+$75.6M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$71.5M
3
ILMN icon
Illumina
ILMN
+$62.5M
4
AZN icon
AstraZeneca
AZN
+$55.2M
5
TSCO icon
Tractor Supply
TSCO
+$51.8M

Sector Composition

Rank Sector Weight
1 Healthcare 43.48%
2 Miscellaneous 31.17%
3 Consumer Discretionary 9.47%
4 Consumer Staples 8.21%
5 Technology 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$812B
$1.2B 20.76%
+3,350,000
New +$1.33B
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$80.4B
$594M 10.3%
+3,600,000
New +$657M
INCY icon
3
Incyte
INCY
$25.4B
$158M 2.74%
2,366,000
+366,000
+18% +$27M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.47B
$155M 2.7%
4,593,004
-118,996
-3% -$3.87M
PTCT icon
5
PTC Therapeutics
PTCT
$5.78B
$146M 2.53%
2,900,000
-396,000
-12% -$19.4M
TVTX icon
6
Travere Therapeutics
TVTX
$6.19B
$144M 2.49%
5,836,000
+516,000
+10% +$13.3M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.8B
$141M 2.44%
1,324,000
– –
FRPT icon
8
Freshpet
FRPT
$3.31B
$137M 2.38%
2,736,000
+1,936,000
+242% +$91.3M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$133M 2.3%
1,900,000
-148,000
-7% -$11M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$395M
$107M 1.86%
2,072,000
+2,000
+0.1% +$117K
GSK icon
11
GSK
GSK
$97.5B
$106M 1.84%
+3,600,000
New +$136M
ROST icon
12
Ross Stores
ROST
$72.9B
$97.6M 1.69%
1,158,117
+957,849
+478% +$81.3M
REGN icon
13
Regeneron Pharmaceuticals
REGN
$83.6B
$93.7M 1.63%
136,000
-52,000
-28% -$32.7M
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$88.2M 1.53%
4,768,000
-632,000
-12% -$9.92M
PCRX icon
15
Pacira BioSciences
PCRX
$1.03B
$84.7M 1.47%
1,592,000
+1,000,000
+169% +$55.6M
ALKS icon
16
Alkermes
ALKS
$7.75B
$84.7M 1.47%
3,792,000
+868,000
+30% +$22.6M
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.3B
$80.3M 1.39%
1,236,000
+136,000
+12% +$9.45M
FIVE icon
18
Five Below
FIVE
$14B
$76.2M 1.32%
+553,231
New +$72.6M
LULU icon
19
lululemon athletica
LULU
$11.4B
$73.1M 1.27%
261,475
+32,902
+14% +$10.2M
ORLY icon
20
O'Reilly Automotive
ORLY
$69.6B
$70.5M 1.22%
1,503,915
-679,800
-31% -$31.7M
LOW icon
21
Lowe's Companies
LOW
$114B
$62.6M 1.09%
333,132
+195,587
+142% +$38.1M
CRSP icon
22
CRISPR Therapeutics
CRSP
$5.28B
$60.4M 1.05%
924,000
-76,000
-8% -$5.51M
BIIB icon
23
Biogen
BIIB
$31.6B
$59.8M 1.04%
224,000
-12,000
-5% -$2.55M
MDT icon
24
Medtronic
MDT
$119B
$58.5M 1.01%
724,000
-76,000
-10% -$6.83M
KYNB
25
Kyntra Bio
KYNB
$33.2M
$58M 1.01%
178,240
+14,560
+9% +$4.69M
1
2 3 4 5

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Armistice Capital held 248 positions worth $5.76B, up 0.57% from $5.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Armistice Capital deployed $188M of net new capital in Q3 2022, opening 70 new positions and adding to 46 existing holdings. Its largest new stake was GSK: 3,600,000 shares worth $106M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 44% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $46.6M trimmed.

  • Armistice Capital's largest Q3 2022 buy was GSK: 3,600,000 shares worth $106M.
  • Armistice Capital added most to Freshpet in Q3 2022, an estimated $91.3M increase.
  • Armistice Capital's biggest Q3 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $46.6M.
  • Armistice Capital fully exited Dollar General in Q3 2022, selling an estimated $75.6M.
  • Armistice Capital's ten largest holdings make up 50% of its $5.76B portfolio in Q3 2022.
  • Armistice Capital opened 70 new positions and closed 50 in Q3 2022.
  • Armistice Capital's portfolio value rose 0.57% quarter-over-quarter to $5.76B.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.